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Abstract
Background: Peroxisome proliferator-activated receptor-g co-activator (PGC)-1a is a transcriptional co-activator of
antioxidant genes and a master regulator of mitochondrial biogenesis. Parkinson’s disease (PD) is associated with
oxidative stress and mitochondrial dysfunction and recent work suggests a role for PGC-1a. We hypothesized that
the rs8192678 PGC-1a single nucleotide polymorphism (SNP) may influence risk or age of onset of PD. The
A10398G mitochondrial SNP has been inversely associated with risk of PD in some studies. In the current study we
analyzed whether rs8192678 or other PGC-1a SNPs affect PD risk or age of onset, singularly or in association with
the A10398G SNP.
Methods: Genomic DNA samples from 378 PD patients and 173 age-matched controls were analyzed by
multiplexed probe sequencing, followed by statistical analyses of the association of each SNP, alone or in
combination, with risk or age of onset of PD. Adjustments were made for age of onset being less than the age of
sampling, and for the observed dependence between these two ages. The PD samples were obtained as two
separate cohorts, therefore statistical methods accounted for different sampling methods between the two cohorts,
and data were analyzed using Cox regression adjusted for sampling in the risk set definition and in the model.
Results: The rs8192678 PGC-1a SNP was not associated with the risk of PD. However, an association of the PGC-1a
rs8192678 GG variant with longevity was seen in control subjects (p = 0.019). Exploratory studies indicated that the
CC variant of rs6821591 was associated with risk of early onset PD (p = 0.029), with PD age of onset (p = 0.047),
and with longevity (p = 0.022). The rs2970848 GG allele was associated with risk of late onset PD (p = 0.027).
Conclusions: These data reveal possible associations of the PGC-1a SNPs rs6821591 and rs2970848 with risk or age
of onset of PD, and of the PGC-1a rs8192678 GG and the rs6821591 CC variants with longevity. If replicated in
other datasets, these findings may have important implications regarding the role of PGC-1a in PD and longevity.
Background
Parkinson’s disease is the second most common age-
related neurodegenerative disease [1]. PD is character-
ized in part by a loss of dopaminergic neurons in the
substantia nigra, which leads to less dopamine release in
the striatum and ultimately to impaired physical move-
ment. PD is a complex disorder involving multiple
genetic and environmental factors [2]. Mutations in a
number of genes including a-synuclein (SNCA), Parkin,
Leucine-Rich-Repeat-Kinase 2 (LRRK2), Phosphatase
and Tensin (PTEN) Homolog-Induced Putative Kinase 1
(PINK1) and DJ-1 among others can cause PD or
increase the risk of PD [3-6]. A mitochondrial complex
I NADH dehydrogenase subunit 3 (ND3) allelic variant,
10398G, has been associated with a decreased risk of
PD in some studies [7,8], but not in others [9-11].
These studies reveal that several genes that regulate
mitochondrial function or oxidative stress also influence
the risk of PD [12-14]. This work, along with that out-
lining the neurological phenotype of the Pgc-1a knock-
out mouse [15], led us to consider PGC-1a,w h i c h
codes for a critical regulator of mitochondrial metabo-
lism, as a candidate susceptibility gene for PD. PGC-1a
is a multifunctional protein that activates most nuclear
receptors and also functions as a co-activator to many
transcription factors with the net result of co-ordinately
regulating mitochondrial biogenesis [16]. PGC-1a links
metabolic activity to relevant environmental stimuli in
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any medium, provided the original work is properly cited.multiple pathways including those responsible for adipo-
genesis, gluconeogenesis, myogenesis and mitogenesis
[17]. In addition, PGC-1a can co-ordinate the expres-
sion of many antioxidant programs in response to oxi-
dative stress [15,18,19]. PGC-1a is important for
protection against MPTP toxicity [15] and levels of
PGC-1a are reduced in substantia nigra neurons in PD
[20], suggesting a role for PGC-1a in the pathogenesis
of PD.
Because PGC-1a is involved with gluconeogenesis,
many association studies have focused on the link
between polymorphisms in the PGC-1a gene and dia-
betes. A number of studies have implicated the
rs8192678 PGC-1a G1444A polymorphism, which con-
verts a glycine to a serine (Gly482Ser) and has been
linked to impaired PGC-1a activity [21] as well as to
glucose intolerance and diabetes [22-29]. A recent study
established an additive interaction for the association
between increased type 2 diabetes mellitus (T2DM) risk
and the PGC-1a 1444A, UCP2 866G and ND3 10398A
genotypes [30]. Further work has implicated the
rs7665116 and rs6821591 non-coding PGC-1a poly-
morphisms with age of onset in Huntington’sd i s e a s e
[31,32].
The A10398G transversion in the mitochondrial com-
plex I NADH dehydrogenase subunit 3 (ND3)g e n e
changes the penultimate amino acid from alanine to
threonine (Thr47Ala) [33]. In some studies the G allele
has been associated with a decreased risk of PD [7,8],
whereas in other studies no association has been found
between the 10398G allelic variant and PD [9,10]. Also,
as a mitochondrial DNA (mtDNA) SNP, the ND3 geno-
type may interact with other genes that influence mito-
chondrial activity, such as any functional PGC-1a SNPs
[30].
Interestingly, patients with PD are more likely to have
glucose intolerance [34], and type 2 diabetes is asso-
ciated with an increased risk of Parkinson’s disease [35].
Furthermore, the symptoms of PD are more severe in
diabetic individuals [36]. We now report results of our
investigation into the association of the rs8192678 PGC-
1a polymorphism with risk for PD and age of onset of
PD, either alone or in combination with the A10398G
mtDNA polymorphism and exploratory analyses of the
association of 14 other PGC-1a SNPs and the A10398G
mtDNA polymorphism with PD.
Methods
Samples
Genomic DNA samples from human blood samples
were obtained from the National Institute of Neurologi-
cal Disorders and Stroke (NINDS) Human Genetics
DNA and Cell Line Repository at the Coriell Institute
for Medical Research (Camden, New Jersey). The first,
detection cohort of samples (PD Cohort 1) consisted of
DNA from 179 Caucasian PD patients. The second, vali-
dation cohort of samples (PD Cohort 2) consisted of
DNA from 199 Caucasian PD patients with either earlier
onset PD (age 35-55 years) or later onset PD (age 63-87
years) and from 173 age-matched Caucasian controls.
The two cohorts of samples were further divided into
subgroups for exploratory statistical analyses as follows:
PD-ALL: all PD samples from both cohorts; PD-Cohort
1: the original cohort of PD samples, which were not
selected for age of onset; PD-Cohort 2: all of the PD
samples comprising the second group of samples that
were selected for age of onset; PD-EARLY: samples
from PD-Cohort 2 with ages of onset between 35 to 55
years; PD-LATE: samples from PD-Cohort 2 with ages
of onset between 63 to 87 years; PD-ALL-EARLY: the
PD-EARLY samples plus those from PD-Cohort 1
within the 35 to 55 year range; PD-ALL-LATE: the PD-
LATE samples plus those from PD-Cohort 1 within the
63 to 87 year range.
Screening of Samples by sequencing and Polymerase
Chain Reaction-Restriction Fragment Length
Polymorphism (PCR-RFLP)
The samples were genotyped using Sequenom
®iPLEX
genotyping at the Harvard-Partners Center for Genetics
and Genomics Genotyping Facility (Cambridge, MA).
The rs8192678 PGC-1a SNP was studied because of the
association of this SNP with other diseases [22-30] and
the A10398G mtDNA variant was chosen for study
because of previous work that possibly links this SNP
with decreased risk of PD [7-10]. The secondary PGC-
1a SNPs were chosen based on previous work that stu-
died the association of PGC-1a with Huntington’sd i s -
ease [31,32]. However, it was not possible to include
one PGC-1a SNP from haplogroup 1 (rs17576121) in a
single iPlex reaction with the other PGC-1a SNPs to be
studied. Because the previous authors [31,32] did not
show association between any of the haplogroup 1 SNPs
and Huntington’s disease we omitted this SNP from the
study.
For purposes of quality control, a subset of samples
were analysed for all polymorphisms using the polymer-
ase chain reaction-restriction fragment length poly-
morphism (PCR-RFLP) method. Where possible,
previously published primers sequences were used in
this study [10,26,37]. Otherwise, primers were designed
using the Primer3 program [38] and checked for
sequence specificity against the NCBI database using
primer-blast (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/). The sequences of these primers are listed in
t a b l eS 1( s e ea d d i t i o n a lf i le 1.). PCR was performed
using 1.25 U of AmpliTaq Gold (Applied Biosystems,
Foster City, California, USA) with annealing at 54-59°C
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at 50°C for 30s for the mtDNA SNP. The PGC-1a PCR
products were digested using the restriction endonu-
cleases listed in table S1 (see additional file 1 ) and the
A10398G mtDNA polymorphism was analyzed by
restriction digest as previously described [10]. All
enzymes were obtained from New England Biolabs, Bev-
erly, Massachusetts, USA).
Statistical Methods
Association of PGC-1a and ND3 A10398G SNPs with risk of
PD
To assess the association of the PGC-1a SNPs or the
A10398G mtDNA variant with risk of PD, we fit condi-
tional logistic regression models for case/control status,
with adjustment for each of the 16 genotypes individu-
ally, and separately for early and late onset cases using
the PD-ALL-EARLY and PD-ALL-LATE cohorts,
respectively. The separate analysis of early (PD-ALL-
EARLY) and late onset cases (PD-ALL-LATE) with their
matched controls recognizes that there may be different
genetic mechanisms that vary by age. However, we also
jointly analyzed all matched cases and controls. We con-
ditioned on age of PD onset for the PD cases and age of
blood sampling for the controls in the models. Based on
o u rs a m p l es i z e s ,w ee s t i m a t e( u s i n gt h eo n l i n ec a l c u l a -
tor, http://prevention.cancer.gov/programs-resources/
groups/b/software/power), that we have roughly 80%
power to detect odds ratios for association between PD
and genotype of 1.4-2.0 or larger (or 0.5-0.7 or smaller),
based on two-sided 0.05 level tests. We also fit all 15
models with the ND3 A10398G SNP and each of the
PGC-1a SNPs and their two-way interactions, again
separately for the PD-ALL-EARLY and PD-ALL-LATE
cohorts.
The validity of these models for assessment of associa-
tion of SNP with risk of PD depends on the assumption
that given age of PD onset, the genotype distribution is
independent of the age of blood sampling for the PD
cases. That is, if the PD cases available to be sampled
have a different genotype distribution from those PD
cases that are removed from the population by early
death or other unavailability for blood sampling, then
this analysis would not be valid. We partially tested this
assumption by fitting logistic regression models for gen-
otype for the PD cases only, with covariate adjustment
for age of PD onset and age of blood sampling (both
continuous and dichotomized at the sample median of
five years post onset). We fit these models separately for
the PD-ALL-EARLY and PD-ALL-LATE cohorts. Age of
blood sampling, dichotomized at five years after diagno-
sis, was significantly associated with rs2970865 (p =
0.043) and with rs2970866 (p = 0.036) in the PD-ALL-
LATE cohort. We used a 0.05 threshold, without any
adjustment for multiple comparisons; this is conserva-
tive, as this will identify violations of the independence
assumption more frequently than if had we used a lower
significance level. Thus, we restricted the analysis of the
association of these SNPs with risk of PD in this cohort
to those PD subjects who provided samples within five
years of diagnosis. This would diminish the bias due to
sampling if these cases were more similar to the popula-
tion of PD patients as a whole at the time of diagnosis.
Association of PGC-1a and ND3 A10398G SNPs with age-of-
onset of PD
To assess the association of the SNPs with age-of-onset
of PD, we used Cox regression models for age of onset
of PD, with adjustment for the right truncation of age of
PD onset by age at blood sampling. We fit this using the
TPHREG procedure in SAS Version 9, after transform-
ing this into a left-truncation setting via “time reversal.”
To adjust for the dependence between the age at blood
sampling and the age of onset (over the observable
region in which the first age necessarily follows the sec-
ond), we included age at blood sampling in the model
[39]. We did this in three ways: (1) including the contin-
uous age as a covariate, (2) including tertiles of age at
blood sampling as covariates, and (3) stratifying by ter-
tiles of age at blood sampling. We applied this analysis
to the PD-ALL-EARLY cohort, to the PD-ALL-LATE
cohort, and to the PD-Cohort 1 cohort. We could not
use the controls in this analysis (as censored for PD
onset) because of their age-based selection. We estimate
that we have 80% power to detect hazard ratios of 1.4-
2.0 or larger (or 0.5-0.7 or smaller), using two-sided,
0.05 level tests; this is a rough calculation that does not
take into account the adjustment for the truncation. We
also used an alternative, cruder approach that obviated
the need to treat the truncation by age at sampling. For
this we used Fisher’s exact test to assess the association
between early (< 55) versus late (> 63) onset and geno-
type using the combined PD-ALL-EARLY and PD-ALL-
LATE cohorts. Based on this analysis, we estimate that
we will have roughly 80% power to detect differences in
genotype prevalences among the early versus late groups
of 10-20% or larger, using two-sided, 0.05 level tests.
Association of PGC-1a and ND3 A10398G SNPs with
longevity
A genotype that appears to be associated with age of
onset of PD might actually be associated with longevity,
and not PD. We control for this in our analysis of risk
of PD by matching on age. We do not control for this
directly in our analysis of continuous age of onset of
PD, in which we are not able to include the normal con-
trols. To assess the association of the SNPs with longev-
ity, we analyzed their associations with the age group of
the controls, i.e., < 55 versus > 63. If any SNPs were
associated with survival, we would expect to find a
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controls versus the older controls. We tested this using
two-sided Fisher’s exact tests. We have approximately
80% power to detect differences in genotype prevalences
among the two groups of 10-20% or larger, using two-
sided, 0.05 level tests. We also assessed the association
of SNPs with age using two-sided Wilcoxon or Kruskal-
Wallis tests to compare the distributions of age between
genotypes.
Multiple comparisons and power
Because of our ap r i o r iinterest in the rs8192678 SNP,
we view the questions surrounding the rs8192678 SNP
as being of primary interest. Because the remaining 15
SNPs did not have strong biological or clinical justifica-
tion, we view their analysis, as well as the analysis of
their interactions with rs8192678, as secondary and
exploratory. Thus, we do not adjust any tests for multi-
ple comparisons. We have provided approximations to
the power that our study had for the analyses of inter-
est. These are crude due to the complex nature of some
of the analyses due to the adjustments for truncation.
Nonetheless, they place the results in perspective and
illustrate that in some cases, we could only have
detected large associations.
Results
General Characteristics of participants
Two separate cohorts of PD DNA samples were
obtained from the NINDS Human Genetics DNA and
Cell Line Repository at the Coriell Institute for Medical
Research (see table 1). The first, detection cohort of 179
PD samples (102 males and 77 females) were randomly
selected from among the available Caucasian PD cases
and initially screened for PGC-1a rs8192678 and ND3
A10398G polymorphisms. The mean age of PD onset
for this selected cohort who provided blood samples at
varying times after their onset was 58.8 in the male
group and 57.2 in the female group, giving rise to an
overall mean age of onset of 58 years in this group. An
initial analysis indicated a non-significant trend towards
an association of the rs8192678 PGC-1a polymorphism
with age of onset of PD. Because of this, the second, or
validation cohort of 197 Caucasian PD samples (also
obtained from the NINDS Human Genetics DNA and
Cell Repository at the Coriell Institute for Medical
Research) was divided into an earlier age of onset group
(35-55 years) and a later age of onset group (63-87
years). Overall, the mean age of onset for this second
cohort, again who provided blood samples at varying
times after PD onset, was 47.7 years for males and 45.7
years for females in the early-onset group and 74.7 for
males and 76.1 for females in the late onset group.
These age ranges were selected as they provided the
maximum separation in ages between the earlier and
later onset groups while still providing the desired num-
bers of samples from the available Caucasian PD sam-
ples at the NINDS Human Genetics DNA and Cell Line
Repository at Coriell. None of the samples from the
initial group were included in the second cohort. The
control group was selected from the same repository to
provide age-matched Caucasian controls for the samples
in the early-onset and late-onset groups of the second
cohort.
Association of PGC-1a and ND3 A10398G genotypes with
risk of Parkinson’s disease
The frequencies of each SNP are shown in table 2. We
did not detect a significant association between
rs8192678 and risk among those with early onset PD
(p = 0.37) or late onset PD (p = 0.84) or in the com-
bined PD groups (p = 0.71). We also did not detect any
significant interaction effects between any of the PGC-
1a SNPs and the ND3 A10398G SNP for the risk of
early or late onset PD.
However, our secondary analyses identified a signifi-
cant association between rs2970848 and risk of late
onset PD (p = 0.027), with high risk associated with the
GG genotype (OR = 3.8 versus AA genotype and OR =
5.4 versus GA genotype). This SNP was not significantly
associated with risk of early onset PD (p = 0.480), and
this association did not quite reach statistical signifi-
cance in the combined early and late groups (p = 0.063).
We found a significant association between rs6821591
and risk of early onset PD (p = 0.029), with higher risk
associated with the CC genotype (OR = 3.33 versus CT
genotype and OR = 3.05 versus TT genotype). This SNP
was not significantly associated with risk of late onset
PD (p = 0.216) and in the combined early and late
groups it was of borderline significance (p = 0.051).
Association of PGC-1a and ND3 A10398G genotypes with
age-of-onset of Parkinson’s disease
Using the three types of Cox regression models for
adjustment for dependent truncation due to the lag
between blood sampling and PD onset, and using the
various cohorts of PD cases described in the Methods
section, we found no significant association between any
PGC-1a SNP, or the ND3 A10398G SNP, with PD age-
of-onset. Using the alternative, cruder, analysis of asso-
ciation between early versus late onset and genotype for
the PD-EARLY-ALL and PD-LATE-ALL groups, we
found a significant association between rs6821591and
onset (p = 0.047), with 24% of early onset cases versus
32% of the late onset cases having the CC genotype,
46.8% of early onset cases versus 50.3% of late onset
cases having the CT genotype, and 29.2% of early onset
cases versus 17.7% of late onset cases having the TT
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be associated with longevity in controls (see below), and
showed different genotype frequencies in the controls
compared to the PD cases, as expected given the above
finding of association of this SNP with risk of PD
(which controls for age). In particular, among young
controls, the frequency of the CC genotype was only
9.9%, in contrast to the 24% frequency among early
onset PD cases. No association was seen between age of
onset and the rs2970848 SNP. In addition, no significant
interactions associated with age-of-onset of PD were
observed between any of the other PGC-1a SNPs. A
Table 1 Characteristics of the Sample Populations
Male Female Total Population
Gender
PD Cohort 1 102 (57.0%) 77 (43.0%) 179
PD Cohort 2 129 (64.8%) 70 (35.2%) 199
PD EARLY 63 (62.4%) 36 (35.6%) 99
PD LATE 66 (66.0%) 34 (34.0%) 100
PD-ALL 200 (60.8%) 129 (39.2%) 329
PD-EARLY-ALL 99 (57.9%) 72 (42.1%) 171
PD-LATE-ALL 101 (63.9%) 57 (36.1%) 158
Control 113 (65.3%) 60 (34.7%) 173
Control EARLY 49 (60.5%) 32 (39.5%) 81
Control LATE 64 (69.6%) 28 (30.4%) 92
Mean Age of Onset
PD Cohort 1 58.8 (SD 10.6) 57.2 (SD 11.4) 58.0 (SD 11.0)
PD Cohort 2 61.5 (SD 14.7) 60.8 (SD 16.2) 61.2 (SD 15.2)
PD EARLY 47.7 (SD 5.4) 45.7 (SD 6.3) 47.0 (SD 5.8)
PD LATE 74.7 (SD 6.1) 76.1 (SD 5.4) 75.2 (SD 5.9)
PD-ALL 60.4 (SD 13.1) 58.6 (SD 15.0) 59.7 (SD 14.3)
PD-EARLY-ALL 47.6 (SD 5.3) 46.6 (SD 6.3) 47.1 (SD 5.8)
PD-LATE-ALL 72.9 (SD 6.2) 73.8 (SD 6.5) 73.4 (SD 6.4)
Control NA NA NA
Mean Age at Sampling
PD Cohort 1 63.8 (SD 9.8) 62.5 (SD 10.6) 63.2 (SD 10.2)
PD Cohort 2 66.2 (SD 14.6) 65.4 (SD 15.8) 65.8 (SD 15.0)
PD EARLY 52.1 (SD 6.1) 50.8 (SD 6.2) 51.7 (SD 6.1)
PD LATE 79.4 (SD 4.4) 80.5 (SD 4.3) 79.8 (SD 4.4)
PD-ALL 65.3 (SD 13.5) 63.6 (SD 14.3) 64.7 (SD 13.8)
PD-EARLY-ALL 52.9 (SD 6.2) 52.3 (SD 7.0) 52.6 (SD 6.6)
PD-LATE-ALL 77.4 (SD 5.4) 77.7 (SD 6.3) 77.5 (SD 5.9)
Control 61.1 (SD 5.9) 61.5 (SD 5.7) 61.3 (SD 5.8)
Control EARLY 47.9 (SD 5.7) 46.8 (SD 5.6) 47.3 (SD 5.7)
Control LATE 74.3 (SD 6.0) 76.3 (SD 5.8) 75.4 (SD 5.9)
Interval Between Onset and Sampling
PD Cohort 1 5.4 (SD 4.6) 5.5 (SD 4.1) 5.4 (SD 4.8)
PD Cohort 2 4.7 (SD 2.5) 4.7 (SD 2.4) 4.7 (SD 2.5)
PD EARLY 4.6 (SD 2.4) 4.9 (SD 2.7) 4.7 (SD 2.5)
PD LATE 4.7 (SD 2.6) 4.5 (SD 2.2) 4.6 (SD 2.5)
PD-ALL 4.9 (SD 3.5) 5.2 (SD 3.7) 5.0 (SD 3.6)
PD-EARLY-ALL 5.3 (SD 3.9) 5.6 (SD 4.3) 5.5 (SD 4.1)
PD-LATE-ALL 4.5 (SD 3.0) 3.8 (SD 2.6) 4.2 (SD 2.8)
Control NA NA NA
Data are presented for both cohorts and for each subgroup that was analyzed. The PD-ALL, PD- ALL-EARLY and PD-ALL-LATE groups represent subgroups drawn
from both PD cohorts within restricted age parameters. Percentages are calculated from row data.
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SNP Alleles PD-Cohort 1 PD-Cohort 2 PD-ALL PD-EARLY-ALL PD-LATE-ALL All Controls Control EARLY Control LATE
rs12374310 GC 71 (41.5%) 78 (42.4%) 149 (42.0%) 72 (45.9%) 62 (41.3%) 81 (50.6%) 35 (49.3%) 46 (51.7%)
CC 70 (40.9%) 77 (41.8%) 147 (41.4%) 55 (35.0%) 68 (45.4%) 49 (30.6%) 21 (29.6%) 28 (31.5%)
GG 30 (17.6%) 29 (15.8%) 59 (16.6%) 30 (19.1%) 20 (13.3%) 30 (18.8%) 15 (21.1%) 15 (16.8%)
rs2946385 GT 79 (47.0%) 81 (45.5%) 160 (46.2%) 72 (47.4%) 65 (44.5%) 80 (50.3%) 38 (53.5%) 42 (47.7%)
GG 60 (35.7%) 70 (39.3%) 130 (37.6%) 59 (38.8%) 54 (37.0%) 52 (32.7%) 21 (29.6%) 31 (35.2%)
TT 29 (17.3%) 27 (15.2%) 56 (16.2%) 21 (13.8%) 27 (18.5%) 27 (17.0%) 12 (16.9%) 15 (17.1%)
rs2946386 GC 52 (30.8%) 77 (42.1%) 129 (36.5%) 55 (35.7%) 61 (40.7%) 49 (30.4%) 17 (23.6%) 32 (36.0%)
CC 104 (61.5%) 93 (50.8%) 197 (55.9%) 88 (57.2%) 77 (51.3%) 98 (60.9%) 48 (66.7%) 50 (56.1%)
GG 13 (7.7%) 13 (7.1%) 27 (7.6%) 11 (7.1%) 12 (8.0%) 14 (8.7%) 7 (9.7%) 7 (7.9%)
rs2970848 AG 76 (45.0%) 81 (44.3%) 157 (44.6%) 74 (47.7%) 60 (40.5%) 80 (50.0%) 32 (44.4%) 48 (54.5%)
AA 80 (47.3%) 81 (44.3%) 161 (45.7%) 70 (45.2%) 69 (46.6%) 74 (46.3%) 37 (51.4%) 37 (42.0%)
GG 13 (7.7%) 21 (11.4%) 34 (9.7%) 11 (7.1%) 19 (12.9%) 6 (3.7%) 3 (4.2%) 3 (3.5%)
rs2970855 AT 80 (47.0%) 93 (50.5%) 173 (48.9%) 78 (49.7%) 72 (48.3%) 78 (49.1%) 32 (45.1%) 46 (52.3%)
TT 69 (40.6%) 63 (34.3%) 132 (37.3%) 60 (38.2%) 53 (35.6%) 59 (37.1%) 31 (43.7%) 28 (31.8%)
AA 21 (12.4%) 28 (15.2%) 49 (13.8%) 19 (12.1%) 24 (16.1%) 22 (13.8%) 8 (11.3%) 14 (15.9%)
rs2970865 TC 56 (33.2%) 77 (41.6%) 133 (37.6%) 57 (36.5%) 62 (41.3%) 52 (32.3%) 18 (25.0%) 34 (38.2%)
TT 105 (62.1%) 96 (51.9%) 201 (56.8%) 30 (57.7%) 79 (52.7%) 98 (60.9%) 48 (66.7%) 50 (56.2%)
CC 8 (4.7%) 12 (6.5%) 20 (5.6%) 9 (5.8%) 9 (6.0%) 11 (6.8%) 6 (8.3%) 5 (5.6%)
rs2970866 AG 55 (32.2%) 75 (41.4%) 130 (37.0%) 54 (34.8%) 62 (41.9%) 50 (31.5%) 17 (23.6%) 33 (37.9%)
AA 105 (61.4%) 94 (52.0%) 199 (56.5%) 90 (58.1%) 77 (52.0%) 97 (61.0%) 48 (66.7%) 49 (56.3%)
GG 11 (6.4%) 12 (6.6%) 23 (6.5%) 11 (7.1%) 9 (6.1%) 12 (7.5%) 7 (9.7%) 5 (5.8%)
rs2970869 GA 55 (33.1%) 78 (42.2%) 133 (37.9%) 57 (37.0%) 62 (41.6%) 52 (32.1%) 18 (24.7%) 34 (38.2%)
GG 104 (62.7%) 95 (51.3%) 199 (56.7%) 89 (57.8%) 78 (52.4%) 98 (60.5%) 48 (65.8%) 50 (56.2%)
AA 7 (4.2%) 12 (6.5%) 19 (5.4%) 8 (5.2%) 9 (6.0%) 12 (7.4%) 7 (9.5%) 5 (5.6%)
rs2970870 TC 83 (49.4%) 87 (49.1%) 170 (49.3%) 77 (51.0%) 73 (50.0%) 72 (45.6%) 26 (36.6%) 46 (52.9%)
TT 54 (32.1%) 58 (32.8%) 112 (32.4%) 47 (31.1%) 47 (31.1%) 57 (36.1%) 29 (40.9%) 28 (32.2%)
CC 31 (18.5%) 32 (18.1%) 63 (18.3%) 27 (17.9%) 27 (17.9%) 29 (18.3%) 16 (22.5%) 13 (14.9%)
rs2970873 CT 40 (23.4%) 60 (33.0%) 100 (28.3%) 40 (25.3%) 48 (32.6%) 41 (25.8%) 15 (21.1%) 26 (29.6%)
CC 126 (73.7%) 116 (63.7%) 242 (68.6%) 114 (72.2%) 93 (63.3%) 114 (71.7%) 53 (74.7%) 61 (69.3%)
TT 5 (2.9%) 6 (3.3%) 11 (3.1%) 4 (2.5%) 6 (4.1%) 4 (2.5%) 3 (4.2%) 1 (1.1%)
rs4383605 TG 59 (35.1%) 73 (40.1%) 132 (37.7%) 55 (35.7%) 60 (40.5%) 59 (37.1%) 25 (35.2%) 34 (38.6%)
TT 89 (53.0%) 97 (53.3%) 186 (53.1%) 84 (54.6%) 77 (52.0%) 83 (52.2%) 37 (52.1%) 46 (52.3%)
GG 20 (11.9%) 12 (6.6%) 32 (9.2%) 15 (9.7%) 11 (7.4%) 17 (10.7%) 9 (12.7%) 8 (9.1%)
rs6821591 CT 92 (53.8%) 83 (46.3%) 175 (50.0%) 72 (46.8%) 74 (50.3%) 80 (50.3%) 40 (56.3%) 40 (45.4%)
CC 39 (22.8%) 54 (30.2%) 93 (26.8%) 37 (24.0%) 47 (32.0%) 31 (19.5%) 7 (9.9%) 24 (27.3%)
TT 39 (22.8%) 42 (23.5%) 81 (23.2%) 45 (29.2%) 26 (17.7%) 48 (30.2%) 24 (33.8%) 24 (27.3%)
rs7665116 CT 39 (22.8%) 43 (23.2%) 82 (23.0%) 41 (25.9%) 31 (20.7%) 56 (35.0%) 26 (36.1%) 30 (34.1%)
TT 128 (74.9%) 140 (75.7%) 268 (75.3%) 114 (72.2%) 119 (79.3%) 102 (63.8%) 45 (62.5%) 57 (64.8%)
CC 4 (2.3%) 2 (1.1%) 6 (1.7%) 3 (1.9%) 0 (0.0%) 2 (1.2%) 1 (1.4%) 1 (1.1%)
rs7695542 CT 17 (10.1%) 9 (4.9%) 26 (7.4%) 41 (26.0%) 31 (20.7%) 15 (9.3%) 8 (11.1%) 7 (7.9%)
TT 151 (89.9%) 176 (95.1%) 327 (92.6%) 114 (72.1%) 119 (79.3%) 145 (90.1%) 64 (88.9%) 81 (91.0%)
CC 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (1.9%) 0 (0.0%) 1 (0.6%) 0 (0.0%) 1 (1.1%)
rs8192678 GA 95 (53.0%) 88 (44.3%) 183 (48.4%) 89 (52.7%) 69 (43.7%) 83 (48.0%) 47 (58.0%) 36 (39.1%)
GG 70 (39.2%) 93 (46.7%) 163 (43.1%) 66 (39.0%) 75 (47.5%) 73 (42.2%) 26 (32.1%) 47 (51.1%)
AA 14 (7.8%) 18 (9.0%) 32 (8.5%) 14 (8.3%) 14 (8.9%) 17 (9.8%) 8 (9.9%) 9 (9.8%)
ND3 A10398G A 143 (79.9%) 149 (75.6%) 292 (77.7%) 132 (79.0%) 119 (75.3%) 129 (74.6%) 60 (74.1%) 69 (75.0%)
G 36 (20.1%) 48 (24.3%) 84 (22.3%) 35 (21.0%) 39 (24.7%) 44 (25.4%) 21 (25.9%) 23 (25.0%)
Data are presented for both cohorts and for each subgroup that was analyzed. The PD-ALL, PD- ALL-EARLY and PD-ALL-LATE groups represent sub-groups drawn
from both PD cohorts within restricted age parameters. Percentages are calculated from column data.
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and the ND3 A10398G SNP was observed in the PD-
Cohort 1 subset of samples, with the concurrence of the
AT and A genotypes being associated with increased
later onset. There was a trend toward this observation
in the PD-ALL-EARLY subset (p = 0.076), but was not
replicated across other PD sample groups. A significant
(p = 0.044) interaction was also found between the
PGC-1a rs7695542 and ND3 A10398G SNPs in the
PD-ALL-LATE cohort, with the combined CT and A
genotypes conferring earlier age of onset, but this was
not replicated across other PD subgroups.
Association of the PGC-1a rs8192678 and rs6821591
polymorphisms with longevity
A significant association between PGC-1a rs8192678
genotype and age group for control subjects was seen
using a two-sided Fisher’s exact test (p = 0.031). 58% of
the 35-55 year old group had the AG genotype, versus
39.1% of the older controls; and 32.1% of the younger
controls had had the GG genotype versus 51.1% of the
older controls. The frequency of the AA genotype was
comparable between the groups (9.8% and 9.9%). A sig-
nificant association between PGC-1a rs6821591 geno-
type and age group for control subjects was also seen
using a two-sided Fisher’s exact test (p = 0.022). 9.9% of
the younger controls had the CC genotype versus 27.3%
of the older controls; 56.3% of the 35-55 year old group
had the CT genotype, versus 45.4% of the older controls
and 33.8% of the younger controls had the TT genotype
versus 27.3% of the older controls. These distributions
appear different from those in the PD cases, which is
confirmed by the significance of the association of this
SNP with PD risk reported above. No significant asso-
ciations were detected between any SNP genotype and
actual age of sampling for the control subjects within
the younger cohort or within the older cohort.
Discussion
Mitochondrial dysfunction and oxidative stress have
been strongly linked to PD [12,13]. PGC-1a, which reg-
ulates mitochondrial biogenesis and expression of many
antioxidant genes, plays an important role in protection
against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) toxicity [15], and expression of genes regulated
by PGC-1a are reduced in substantia nigra neurons at
early stages of PD [20]. These data led us to examine
the association of common and potentially functionally
relevant SNPs in the gene encoding PGC-1a with the
risk of PD and age of onset of PD. A common mito-
chondrial complex I ND3 gene variant, 10398G, has
been reported in some studies to be associated with
decreased risk of PD, and thus we also examined the
PGC-1a SNPs independently and in conjunction with
the A10398G ND3 SNP for an association with risk of
PD or age of onset of PD.
We did not find an association between the PGC-1a
rs8192678 SNP and risk of PD or age-of-onset of PD.
However, a significant association between the PGC-1a
rs8192678 genotype and age group was found in our set
of control subjects, with the GG genotype being signifi-
cantly more common in older controls and the AG gen-
otype more common in younger controls. This may
suggest an association of the GG genotype with longev-
ity. Potentially, this may be because the presence of the
A allele has been associated with conditions detrimental
to health such as diabetes, coronary artery disease,
severe hypertension and alcohol consumption [40-46]
whereas the GG genotype has been associated with
lower fasting insulin levels [26]. Arguing against this
explanation is our finding of a comparable frequency of
the AA PGC-1a genotype the younger and older control
groups. However, it is possible that the detrimental
effect of the AA genotype may occur at an age even
younger than that of our young control group (which
was ages 35 - 55). An alternative interpretation of these
data is that, rather than an effect on longevity, this
PGC-1a variant could be associated with factors that
influence the chances of volunteering to be a control
subject at younger versus older ages.
There were no significant associations of the A10398G
polymorphism with age group, either in the control
population or the PD population. We also found no
consistent association of the 10398G variant with risk of
PD or age of onset of PD. Though this variant has been
reported previously to be associated with a lower risk of
PD, this finding has been variable across studies
[7-11,47]. Differences in ethnicities may account for
some of the apparent discrepancies, with a positive
report in Caucasians [8] and in a Spanish population
[48] and negative reports in Italian [9] and Greek popu-
lations [47]. However, other prior studies also had failed
to detect a difference in analyses or sub-analyses of only
Caucasian subjects [10,11,49].
Exploratory analyses identified that the rs2970848 GG
variant may be associated with increased risk of late
onset PD, but was not associated with the risk of early
onset PD, or with the age of onset of PD when compar-
ing frequencies in the later-onset and earlier-onset PD
groups. The rs6821591 CC variant was associated with
increased risk of earlier-onset PD (present at a higher
frequency in earlier-onset PD patients compared to age-
matched controls). Therefore, it may appear surprising
that the CC variant was seen at a lower frequency in the
earlier-onset PD patients (24%) compared to the fre-
quency in the later-onset PD patients (34%). However,
these observations are not contradictory. The finding of
association with risk is within the younger groups and
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Page 7 of 9thus controls for age. That is, restricting to the younger
groups, there is still a greater prevalence of the CC var-
iant among PD patients compared to controls. Interest-
ingly, one previous study [32] revealed an association of
the rs6821591 SNP with delayed age of onset in Hun-
tington’s disease.
This is the first study to examine the association
between PGC-1a single-nucleotide polymorphisms and
PD. Variants of the rs8192678 PGC-1a polymorphism
have previously been studied alongside polymorphisms
in peroxisome proliferator-activated receptor delta
(PPARD) and sirtuin 1 (SIRT1) in relation to Alzhei-
mer’s disease and were found not to be associated with
AD in a Finnish case-control situation [50]. Two recent
independent studies reported that PGC-1a haplotypes
may be important modifiers for age of onset in Hunting-
ton Disease [31,32]. While the current results provide
only limited evidence for a role for common PGC-1a
variants in PD, a broader examination of PGC-1a SNPs
is required before concluding whether or not other
PGC-1a variants influence PD risk or age of onset.
Conclusions
These data provide limited evidence of an association of
certain PGC-1a SNPs with the risk or age of onset of
PD, but the results are of borderline significance and as
an exploratory study these findings require confirmation
in separate cohorts. The association of the PGC-1a
rs8192678 GG and rs6821591 CC variants with longev-
ity deserves further study.
Additional material
Additional file 1: List of primers and restriction enzymes used in
this study.
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